CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA019796 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA019796.

Normal code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Normal
0

Critical

0%

0

High

0%

1

Routine

100%

0

Low

0%

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ELOCON (MOMETASONE FUROATE) — Type 3 - New Dosage Form

Policy FDA-NDA019796 · Dermatology

Routine

Elocon (mometasone furoate) Lotion is a topical corticosteroid approved under NDA019796, administered via the topical route, placing it squarely in the Part D billing pathway as a self-administered ou

View alert

Audit documentation

Building an audit file that includes FDA-NDA019796?

The Tripwire Audit Pack exports 12 months of Dermatology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Dermatology audit pack — $349One-time purchase · not a subscription